Cardioprotective and Anti-inflammatory Effects of FAM3D in Myocardial Ischemia-Reperfusion Injury

Human plasma samples from patients with acute myocardial infarction (AMI) were obtained at 14-28 days and 6 months after index event, as part of the OMEGA-REMODEL Trial [Heydari, B., et al., Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial. Circulation, 2016. 134(5): p. 378-91]. Patients were enrolled across 3 tertiary-care centers in Boston, MA, with each of their Institutional Review Boards approving the study (Brigham and Women’s, Massachusetts General, and Beth Israel Deaconess Medical Center hospitals). All patients received standard medical therapy per discretion of their attending cardiologists. Please refer to Heydari et al. for inclusion and exclusion criteria, and study endpoints. The primary study endpoint was change in left ventricular end-systolic volume indexed to body surface area (LVESVI, mL/m2) by cardiac MRI over 6 months.  Blood samples were anticoagulated with EDTA, and plasma immediately stored at -80C with minimal number of freeze-thaw cycles before proteomic analysis. An aptamer-based proteomics platform (version 3,Somalogic) was used to measure relative levels of 1,305 analytes, corresponding to 1,1272 unique human proteins.